WallStreetZenWallStreetZen

NASDAQ: GANX
Gain Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GANX

Based on 4 analysts offering 12 month price targets for Gain Therapeutics Inc

Min Forecast
$6.00+244.83%
Avg Forecast
$8.25+374.14%
Max Forecast
$12.00+589.66%

Should I buy or sell GANX stock?

Based on 4 analysts offering ratings for Gain Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GANX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates GANX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their GANX stock forecasts and price targets.

GANX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-28
lockedlocked$00.00+00.00%2025-03-17
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2024-12-24

1 of 1

Forecast return on equity

Is GANX forecast to generate an efficient return?

Company
-810.18%
Industry
153.19%
Market
81.87%
GANX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GANX forecast to generate an efficient return on assets?

Company
-490.47%
Industry
36.07%
GANX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GANX earnings per share forecast

What is GANX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.70
Avg 2 year Forecast
-$1.13

GANX revenue forecast

What is GANX's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$200.0k

GANX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GANX$1.74$8.25+374.14%Strong Buy
ICCC$5.38N/AN/A
CUE$0.78$2.00+156.08%Buy
SKYE$1.57$14.50+823.57%Buy
PDSB$1.08$10.00+825.93%Strong Buy
View Top Biotech Stocks

Gain Therapeutics Stock Forecast FAQ

Is Gain Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: GANX) stock is to Strong Buy GANX stock.

Out of 4 analysts, 2 (50%) are recommending GANX as a Strong Buy, 2 (50%) are recommending GANX as a Buy, 0 (0%) are recommending GANX as a Hold, 0 (0%) are recommending GANX as a Sell, and 0 (0%) are recommending GANX as a Strong Sell.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.

What is GANX's earnings growth forecast for 2025-2026?

(NASDAQ: GANX) Gain Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Gain Therapeutics's earnings in 2025 is -$20,411,191.On average, 3 Wall Street analysts forecast GANX's earnings for 2025 to be -$19,542,563, with the lowest GANX earnings forecast at -$20,284,475, and the highest GANX earnings forecast at -$18,895,127.

In 2026, GANX is forecast to generate -$31,399,256 in earnings, with the lowest earnings forecast at -$31,399,256 and the highest earnings forecast at -$31,399,256.

What is GANX's revenue growth forecast for 2025-2025?

(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Gain Therapeutics's revenue in 2025 is $0.

In 2025, GANX is forecast to generate $5,557,390 in revenue, with the lowest revenue forecast at $5,557,390 and the highest revenue forecast at $5,557,390.

What is GANX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GANX) forecast ROA is -490.47%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is GANX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year GANX price target, the average GANX price target is $8.25, with the highest GANX stock price forecast at $12.00 and the lowest GANX stock price forecast at $6.00.

On average, Wall Street analysts predict that Gain Therapeutics's share price could reach $8.25 by Mar 28, 2026. The average Gain Therapeutics stock price prediction forecasts a potential upside of 374.14% from the current GANX share price of $1.74.

What is GANX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: GANX) Gain Therapeutics's current Earnings Per Share (EPS) is -$0.89. On average, analysts forecast that GANX's EPS will be -$0.70 for 2025, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at -$0.68. In 2026, GANX's EPS is forecast to hit -$1.13 (min: -$1.13, max: -$1.13).

What is GANX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GANX) forecast ROE is -810.18%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.